Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mogamulizumab + Nivolumab in Advanced Solid Tumors
NCT02705105Phase 2Completed
- Sponsor
- Kyowa Kirin
- Start
- Feb 2016
- Primary completion
- Aug 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of mogamulizumab in solid tumor, hepatocellular carcinoma (HCC), sponsored by Kyowa Kirin. Started Feb 2016; status: completed.
02
Drugs
mogamulizumab
03
Conditions
solid tumorhepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02705105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02705105.